Carboplatin and paclitaxel in metastatic or recurrent cervical cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 4, 2009, Pages 777-781

  Pectasides, Dimitrios ^a,c   Fountzilas, George ^b   Papaxoinis, George ^a   Pectasides, Eirini ^a   Xiros, Nicolaos ^a   Sykiotis, Constantinos ^a   Koumarianou, Anna ^a   Psyrri, Amanda ^a   Panayiotides, John ^a   Economopoulos, Theofanis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Carboplatin; Cervical cancer; Chemotherapy; Paclitaxel

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; DRUG ACTIVITY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HISTOLOGY; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERFORMANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SENSORY NEUROPATHY; SEPSIS; STATISTICAL SIGNIFICANCE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 67651055446     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a40a8b     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Cadron I, Van Gorp T, Amant F, et al. Chemotherapy for recurrent cervical cancer. Gynecol Oncol. 2007;107 (1 suppl 1): S113-118.
4. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113-3119.
5. Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 1981;48: 899-903.
6. Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3:1079-1085.
7. McGuire WP 3rd, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989;7:1462-1468.
8. McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol. 1996;14:792-795.
9. Kudelka AP, Winn R, Edwards CL, et al. Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Clin Cancer Res. 1996;2:1285-1288.
10. Papadimitriou CA, Sarris K, Moulopoulos LA, et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol. 1999;17:761-766.
11. Rose PG, Blessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1999;17:2676-2680.
12. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No 48). Geneva, Switzerland: World Health Organization; 1979.
13. Sutton GP, Blessing JA, DiSaia PJ, et al. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1993;49:48-50.
14. Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000;77:446-449.
15. Muderspach LI, Blessing JA, Levenback C, et al. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2001;81:213-215.
16. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997;15:625-631.
17. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15:165-171.
18. Piver MS, Ghamande SA, Eltabbakh GH, et al. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix-a phase II study. Gynecol Oncol. 1999;75:334-337.
19. Weiss GR, Green S, Hannigan EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol. 1990;39:332-336.
20. Nagao S, Okimoto N, Hongo A, et al. Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients. Gan To Kagaku Ryoho. 2003;30:243-249.
21. Tinker AV, Bhagat K, Swenerton KD, et al. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol. 2005;98:54-58.
22. Sit AS, Kelley JL, Gallion HH, et al. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix. Cancer Invest. 2004; 22:368-373.
23. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007;105:299-303.
24. Brader KR, Morris M, Levenback C, et al. Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol. 1998;16:1879-1884.
25. Zanetta G, Torri W, Bocciolone L, et al. Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent squamous cell cervical carcinoma: a multivariate analysis. Gynecol Oncol. 1995;58:58-63.
26. Monk BJ, Huang HQ, Cella D, et al. Gynecologic Oncology Group study. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23: 4617-4625.
27. Morris M, Blessing JA, Monk BJ, et al. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3340-3344.